NCT03219957View on ClinicalTrials.gov

Study of AT-527 in Healthy and HCV-Infected Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

July 6, 2017

Primary Completion Date

June 20, 2018

Study Completion Date

June 20, 2018

Conditions
Chronic Hepatitis CHepatitis CHepatitis C, Chronic
Interventions
DRUG

AT-527

Ascending doses of AT-527 administered orally.

OTHER

Placebo Comparator

Matching placebo

Trial Locations (2)

Unknown

Clinical Trial Site, Antwerp

Clinical Trial Site, Chisinau

Sponsors
All Listed Sponsors
lead

Atea Pharmaceuticals, Inc.

INDUSTRY

NCT03219957 - Study of AT-527 in Healthy and HCV-Infected Subjects | Biotech Hunter | Biotech Hunter